跳转至内容
Merck

LncRNA AK023948 is a positive regulator of AKT.

Nature communications (2017-02-09)
Pratirodh Koirala, Jianguo Huang, Tsui-Ting Ho, Fangting Wu, Xianfeng Ding, Yin-Yuan Mo
摘要

Despite the overwhelming number of human long non-coding RNAs (lncRNAs) reported so far, little is known about their physiological functions for the majority of them. The present study uses a CRISPR/Cas9-based synergistic activation mediator (SAM) system to identify potential lncRNAs capable of regulating AKT activity. Among lncRNAs identified from this screen, we demonstrate that AK023948 is a positive regulator for AKT. Knockout of AK023948 suppresses, whereas rescue with AK023948 restores the AKT activity. Mechanistically, AK023948 functionally interacts with DHX9 and p85. Importantly, AK023948 is required for the interaction between DHX9 and p85 to hence the p85 stability and promote AKT activity. Finally, AK023948 is upregulated in breast cancer; interrogation of TCGA data set indicates that upregulation of DHX9 in breast cancer is associated with poor survival. Together, this study demonstrates two previously uncharacterized factors AK023948 and DHX9 as important players in the AKT pathway, and that their upregulation may contribute to breast tumour progression.

材料
货号
品牌
产品描述

Sigma-Aldrich
Duolink® In Situ Red小鼠/兔启动装试剂盒
Sigma-Aldrich
MISSION® esiRNA, targeting human DHX9